Unichem Laboratories [UNICHEMLAB] vs Indraprastha Medical [INDRAMEDCO] Detailed Stock Comparison

Unichem Laboratories Ltd.

NSE
Loading...

Indraprastha Medical Corporation Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Unichem Laboratories Ltd. wins in 10 metrics, Indraprastha Medical Corporation Ltd. wins in 9 metrics, with 0 ties. Unichem Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Unichem Laboratories Ltd. Indraprastha Medical Corporation Ltd. Better
P/E Ratio (TTM) 8.91 20.08 Unichem Laboratories Ltd.
Price-to-Book Ratio 1.08 5.57 Unichem Laboratories Ltd.
Debt-to-Equity Ratio 20.62 4.76 Indraprastha Medical Corporation Ltd.
PEG Ratio 0.02 -5.81 Unichem Laboratories Ltd.
EV/EBITDA 14.37 12.10 Indraprastha Medical Corporation Ltd.
Profit Margin (TTM) 13.32% 12.60% Unichem Laboratories Ltd.
Operating Margin (TTM) 2.60% 13.64% Indraprastha Medical Corporation Ltd.
EBITDA Margin (TTM) 2.60% 13.64% Indraprastha Medical Corporation Ltd.
Return on Equity 5.61% 26.98% Indraprastha Medical Corporation Ltd.
Return on Assets (TTM) 3.85% 18.90% Indraprastha Medical Corporation Ltd.
Free Cash Flow (TTM) $-1.44B $1.20B Indraprastha Medical Corporation Ltd.
Dividend Yield N/A 0.95% N/A
1-Year Return -26.15% -5.84% Indraprastha Medical Corporation Ltd.
Price-to-Sales Ratio (TTM) 1.18 2.53 Unichem Laboratories Ltd.
Enterprise Value $30.22B $32.43B Indraprastha Medical Corporation Ltd.
EV/Revenue Ratio 1.37 2.23 Unichem Laboratories Ltd.
Gross Profit Margin (TTM) 54.51% 37.00% Unichem Laboratories Ltd.
Revenue per Share (TTM) $314 $158 Unichem Laboratories Ltd.
Earnings per Share (Diluted) $41.78 $19.94 Unichem Laboratories Ltd.
Beta (Stock Volatility) -0.21 0.58 Unichem Laboratories Ltd.

Unichem Laboratories Ltd. vs Indraprastha Medical Corporation Ltd. Stock Performance Analysis

Loading Price Chart...

UNICHEMLAB
INDRAMEDCO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Unichem Laboratories Ltd.-1.71%23.27%18.14%42.52%-5.28%0.01%
Indraprastha Medical Corporation Ltd.0.38%-0.95%4.95%-1.44%-21.11%-14.34%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Unichem Laboratories Ltd.-26.15%21.24%39.74%72.55%182.75%381.29%
Indraprastha Medical Corporation Ltd.-5.84%323.69%338.93%635.89%971.03%1,203.39%

Performance & Financial Health Analysis: Unichem Laboratories Ltd. vs Indraprastha Medical Corporation Ltd.

MetricUNICHEMLABINDRAMEDCO
Market Information
Market Cap i₹26.22B₹37.31B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i63,709399,153
90 Day Avg. Volume i56,616289,583
Last Close₹439.95₹385.95
52 Week Range₹278.20 - ₹657.95₹342.00 - ₹640.85
% from 52W High-33.13%-39.78%
All-Time High₹937.95 (Nov 04, 2024)₹640.85 (Nov 06, 2025)
% from All-Time High-53.09%-39.78%
Growth Metrics
Quarterly Revenue Growth-0.02%0.14%
Quarterly Earnings Growth3.57%0.25%
Financial Health
Profit Margin (TTM) i0.13%0.13%
Operating Margin (TTM) i0.03%0.14%
Return on Equity (TTM) i0.06%0.27%
Debt to Equity (MRQ) i20.624.76
Cash & Liquidity
Book Value per Share (MRQ)₹346.08₹71.88
Cash per Share (MRQ)₹27.48₹50.31
Operating Cash Flow (TTM) i₹-1,166,300,000₹1.78B
Levered Free Cash Flow (TTM) i₹1.38B₹1.61B
Dividends
Last 12-Month Dividend Yield iN/A0.95%
Last 12-Month Dividend i₹0.00₹4.50

Valuation & Enterprise Metrics Analysis: Unichem Laboratories Ltd. vs Indraprastha Medical Corporation Ltd.

MetricUNICHEMLAB (Apr 26, 2026)INDRAMEDCO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i8.9120.08
Forward P/E iN/A18.63
PEG Ratio i0.02-5.81
Price to Sales (TTM) i1.182.53
Price to Book (MRQ) i1.085.57
Market Capitalization
Market Capitalization i₹26.22B₹37.31B
Enterprise Value i₹30.22B₹32.43B
Enterprise Value Metrics
Enterprise to Revenue i1.372.23
Enterprise to EBITDA i14.3712.10
Risk & Other Metrics
Beta i-0.210.58
Book Value per Share (MRQ) i₹346.08₹71.88

Financial Statements Comparison: Unichem Laboratories Ltd. vs Indraprastha Medical Corporation Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricUNICHEMLAB (2025)INDRAMEDCO (2025)
Revenue/Sales i20.64B13.07B
Cost of Goods Sold i9.95B8.53B
COGS % of Revenue i48.2%65.3%
Gross Profit i10.69B4.54B
Gross Margin i51.8%34.7%
Research & Development i185.10MN/A
Operating Income (EBIT) i1.40B2.10B
Operating Margin i6.8%16.1%
EBITDA i2.90B2.64B
EBITDA Margin i14.0%20.2%
Pre-Tax Income i1.55B2.16B
Pre-Tax Income % of Revenue i7.5%16.6%
Income Tax i170.70M553.30M
Income Tax % of Revenue i0.8%4.2%
Net Income (Profit) i1.38B1.61B
Profit Margin i6.7%12.3%

Balance Sheet & Liquidity Metrics

MetricUNICHEMLAB (2025)INDRAMEDCO (2025)
Cash & Equivalents i895.80M614.80M
Total Current Assets i20.29B4.31B
Total Current Assets % of Revenue i98.3%33.0%
Total Current Liabilities i9.92B1.79B
Total Current Liabilities % of Revenue i48.0%13.7%
Long-Term Debt i860.00M305.40M
Long-Term Debt % of Revenue i4.2%2.3%
Total Shareholders Equity i24.51B5.97B
Retained Earnings i24.56B4.75B
Retained Earnings % of Revenue i119.0%36.4%
Property, Plant & Equipment i12.79B2.60B

Cash Flow Statement Comparison

MetricUNICHEMLAB (2025)INDRAMEDCO (2025)
Operating Cash Flow i-1.17B1.78B
Operating Cash Flow % of Revenue i-5.6%13.6%
Capital Expenditures i-1.35B-363.30M
Free Cash Flow i-1.44B1.20B
FCF Margin i-7.0%9.2%
Debt Repayment i-256.60MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricUNICHEMLABINDRAMEDCO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i70.41M91.67M
Float Shares i20.06M41.01M
% Held by Insiders i71.31%55.41%
% Held by Institutions i10.05%0.57%
% Held by Public i18.64%44.02%

Dividend Analysis & Yield Comparison: Unichem Laboratories Ltd. vs Indraprastha Medical Corporation Ltd.

MetricUNICHEMLABINDRAMEDCO
Last 12-Month Dividend i₹0.00₹4.50
Last 12-Month Dividend Yield iN/A0.95%
3-Year Avg Annual Dividend i₹1.33₹4.00
3-Year Avg Dividend Yield i1.34%1.26%
3-Year Total Dividends i₹4.00₹12.00
Ex-Dividend DateAug 01, 2022Sep 18, 2025